Severity
Critical
FDA Drug recall · Reported August 14, 2013
Marketed without an approved NDA/ANDA: Product may contain undeclared active pharmaceutical ingredients Diclofenac Sodium, Dexamethasone, and Methocarbamol.
Reumofan Plus USA recalled Reumofan Plus, 30-count tablets per bottle, distriubted by Reumofan Plus USA, LLC and Reu… - a critical-severity action.
Reumofan Plus, 30-count tablets per bottle, distriubted by Reumofan Plus USA, LLC and Reu… was recalled by Reumofan Plus USA in August 14, 2013. Reason: Marketed without an approved NDA/ANDA: Product may contain undeclared active pharmaceutical ingredients Diclo…. Check the official notice for the remedy. Verify recall #D-837-2013 with the FDA Drug before acting.
The recall
Reumofan Plus USA issued this critical-severity FDA Drug recall-Marketed without an approved NDA/ANDA: Product may contain undeclared active pharmaceutical ingredients Diclo….
Sourced from official FDA Drug enforcement records. Verify recall #D-837-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-837-2013) was formally reported on August 14, 2013, with the manufacturer initiating the action on January 4, 2013. It is classified under Critical severity (Class I), with a current status of Terminated. Reumofan Plus USA is listed as the recalling firm, operating out of Springfield, PA. Federal records list the affected scope as 586 bottles.
The documented reason for this recall is: Marketed without an approved NDA/ANDA: Product may contain undeclared active pharmaceutical ingredients Diclofenac Sodium, Dexamethasone, and Methocarbamol. Distribution data in the federal record shows the product reached: Nationwide through internet sales.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
586 bottles
Related Recalls
6
5 from same agency
Reumofan Plus, 30-count tablets per bottle, distriubted by Reumofan Plus USA, LLC and Reumofan USA, LLC, Springfield, PA, and manufactured by Riger Natural S.A., Mexico.
Marketed without an approved NDA/ANDA: Product may contain undeclared active pharmaceutical ingredients Diclofenac Sodium, Dexamethasone, and Methocarbamol.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-837-2013 |
| Date reported | August 14, 2013 |
| Date initiated | January 4, 2013 |
| Recalling firm | Reumofan Plus USA |
| Firm location | Springfield, PA |
| Affected scope | 586 bottles |
| Distribution | Nationwide through internet sales. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 14, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.